$4.05 Billion in Sales Expected for Allergan PLC. (AGN) This Quarter
Wall Street analysts forecast that Allergan PLC. (NYSE:AGN) will post sales of $4.05 billion for the current fiscal quarter, according to Zacks. Sixteen analysts have issued estimates for Allergan PLC.’s earnings. The highest sales estimate is $4.17 billion and the lowest is $3.95 billion. Allergan PLC. posted sales of $3.62 billion in the same quarter last year, which suggests a positive year over year growth rate of 11.9%. The company is scheduled to issue its next quarterly earnings results on Wednesday, November 1st.
On average, analysts expect that Allergan PLC. will report full-year sales of $4.05 billion for the current year, with estimates ranging from $15.82 billion to $16.02 billion. For the next year, analysts expect that the company will post sales of $16.86 billion per share, with estimates ranging from $16.16 billion to $17.57 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Allergan PLC..
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 earnings per share.
Several analysts have recently weighed in on AGN shares. UBS AG reaffirmed a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. ValuEngine lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, June 8th. Finally, Mizuho dropped their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $275.49.
Shares of Allergan PLC. (NYSE AGN) opened at 233.55 on Friday. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company has a 50-day moving average price of $235.62 and a 200 day moving average price of $237.29. The company has a market capitalization of $78.08 billion, a price-to-earnings ratio of 7.12 and a beta of 1.18.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio is 9.95%.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Pathstone Family Office LLC boosted its position in shares of Allergan PLC. by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock worth $2,035,000 after purchasing an additional 366 shares in the last quarter. Howard Hughes Medical Institute bought a new position in shares of Allergan PLC. during the second quarter worth $103,000. Enterprise Financial Services Corp boosted its position in shares of Allergan PLC. by 62.7% during the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after purchasing an additional 178 shares in the last quarter. Jacobi Capital Management LLC boosted its position in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after purchasing an additional 12 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.